P

Prothena Corp
D

PRTA

6.68000
USD
-0.03
(-0.37%)
مغلق
حجم التداول
39,653
الربح لكل سهم
-3
العائد الربحي
-
P/E
-3
حجم السوق
359,564,240
أصول ذات صلة
ALNY
ALNY
1.29
(0.39%)
329.01 USD
AMGN
AMGN
-2.01
(-0.65%)
306.66 USD
C
CRSP
-1.350
(-2.04%)
64.760 USD
E
EDIT
-0.11000
(-3.38%)
3.14000 USD
GILD
GILD
3.000
(2.65%)
116.210 USD
ILMN
ILMN
1.730
(1.61%)
109.330 USD
N
NTLA
0.830
(6.50%)
13.595 USD
REGN
REGN
-1.20
(-0.21%)
563.22 USD
S
SGMO
-0.01190
(-1.99%)
0.58600 USD
المزيد
الأخبار المقالات

العنوان: Prothena Corp

القطاع: Healthcare
الصناعة: Biotechnology
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.